What is the recommended medication regimen for Rapid Sequence Intubation (RSI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Medication Regimen for Rapid Sequence Intubation (RSI)

The recommended medication regimen for rapid sequence intubation consists of a sedative-hypnotic induction agent (etomidate or ketamine) followed by a neuromuscular blocking agent (either succinylcholine or rocuronium). 1

Sedative-Hypnotic Agent Selection

  • Etomidate (0.3 mg/kg IV) is preferred in hemodynamically unstable patients due to its favorable cardiovascular profile with minimal effects on blood pressure 1, 2
  • Ketamine (1-2 mg/kg IV) is an alternative first-line agent with sympathomimetic properties that help maintain hemodynamic stability 1
  • Most studies demonstrate no significant difference in mortality between etomidate and other induction agents, making etomidate a reasonable choice for critically ill patients 2
  • Etomidate may cause transient adrenal suppression, but corticosteroid administration following etomidate is not recommended as studies show no difference in mortality outcomes 2, 1

Neuromuscular Blocking Agent Selection

  • A neuromuscular blocking agent (NMBA) must be administered when a sedative-hypnotic induction agent is used for intubation (strong recommendation) 2
  • Succinylcholine (1-1.5 mg/kg IV) is the first-line NMBA when no contraindications exist 1
  • Caution is warranted with succinylcholine in patients with baseline bradycardia as it has been associated with post-RSI bradycardia (RR = 1.81) 3
  • Rocuronium (0.9-1.2 mg/kg IV) is the preferred alternative when succinylcholine is contraindicated 1, 4
  • For rapid sequence intubation, rocuronium doses of 0.6 to 1.2 mg/kg provide excellent or good intubating conditions in most patients within 2 minutes 4

Medication Administration Sequence

  • The sedative-hypnotic agent must be administered before the neuromuscular blocking agent to prevent awareness during paralysis 1
  • Some evidence suggests that administering the neuromuscular blocking agent first (followed immediately by the sedative) may result in modestly faster time to intubation (approximately 6 seconds shorter) 5
  • Regardless of administration order, both medications should be given in rapid succession (within 30 seconds of each other) 5

Post-Intubation Considerations

  • When using rocuronium, which has a longer duration of action than the sedative effects of etomidate, prompt initiation of post-intubation analgesia and sedation is essential 6
  • The median time to first analgosedative intervention after etomidate-rocuronium RSI is approximately 7 minutes 6
  • Continuous monitoring of vital signs and sedation status is necessary to prevent awareness during prolonged paralysis 6, 7

Special Considerations

  • In patients with sepsis, etomidate (0.3 mg/kg) remains a reasonable choice as studies have not demonstrated negative clinical outcomes from transient adrenal suppression 2, 3
  • For obese patients, dosing should be based on actual body weight rather than ideal body weight to ensure adequate intubating conditions 4
  • RSI with etomidate is not recommended for rapid sequence induction in Cesarean section patients due to poor or inadequate intubating conditions observed in clinical studies 4

Common Pitfalls to Avoid

  • Using etomidate-only intubation without a neuromuscular blocking agent results in significantly worse laryngoscopy conditions and lower intubation success rates compared to complete RSI 8
  • Inadequate post-intubation sedation when using longer-acting paralytics like rocuronium can lead to awareness during paralysis 6, 3
  • Inappropriate use of succinylcholine in patients with contraindications (approximately 13% of cases in observational studies) 3
  • Failure to have reversal agents available when using high-dose rocuronium (≥0.9 mg/kg) 1

References

Guideline

Rapid Sequence Intubation Medication Regimen

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Drug Order in Rapid Sequence Intubation.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2019

Guideline

Sedation for Shoulder Reduction in Obese Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.